Medical cannabis may play a role in managing fibromyalgia and related symptoms of depression and anxiety, according to a peer-reviewed study published in the American Journal of Endocannabinoid Medicine. Three-fourths of the more than 800 patients assessed saw a significant decrease in their self-reported illness severity, according to the study, which was led by researchers at Harvest Medicine, a subsidiary of MediPharm Labs Corp. MEDIF. Fibromyalgia is a chronic condition that affects about 4 million U.S. adults and causes musculoskeletal pain, fatigue and mood issues. Most patients in the study used CBD oil. Roughly half of the patients with severe anxiety or depression saw a reduction in those symptoms. MediPharm specializes in developing and manufacturing cannabis concentrates and active pharmaceutical ingredients. MediPharm stock was unchanged premarket on Thursday and has gained 15.6% in the year to date, while the S&P 500 SPX has gained 17.6%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.